Startup profile · funding coverage
Aiforia funding, valuation and investors
European institutional financing for ai-assisted pathology and cancer detection.
Keep track of Aiforia
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
EIB financing
€20M · August 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
public
public · Helsinki, Finland
Overview
Aiforia is associated with European institutional financing for AI-assisted pathology and cancer detection. On 2026-08-09, it announced €20M in EIB financing. Undisclosed valuation, revenue and financing terms are not inferred.
Why Aiforia is interesting
August 2026: €20M in EIB financing, with the financing type preserved rather than flattened into a generic VC total.
Key facts
- EIB financing: €20M (August 2026)
- Financing classification: EIB financing
- Undisclosed terms remain undisclosed
Funding history (newest first)
EIB financing
2026-08 €20MMarket / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Aiforia's financing or category context.
FAQs about Aiforia
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.